Skip to main content

INVESTIGAIT: A 28 week, randomized, double-blind, placebo-controlled, two-part, multi-center, parallel group dose range finding study to assess the effect of monthly doses of bimagrumab 70, 210, and 700 mg on skeletal muscle strength and function in older

NCT2333331

INVESTIGAIT: A 28 week, randomized, double-blind, placebo-controlled, two-part, multi-center, parallel group dose range finding study to assess the effect of monthly doses of bimagrumab 70, 210, and 700 mg on skeletal muscle strength and function in older adults with sarcopenia

Principal Investigator

Sponsor

Novartis Pharmaceuticals

This clinical research study is being conducted to find out if the drug bimagrumab BYM338 is safe and has beneficial effects in people who have a lower than normal amount of muscle for their age and have difficulty walking or climbing stairs called sarcopenia.